title: [Clinical Efficacy of Cepharanthin(R)for Radiotherapy-Induced Leukopenia - A Nationwide, Multicenter, and Observational Study].
abstract: The clinical efficacy and safety of cepharanthin for the treatment of radiotherapy-induced leukopenia were reevaluated at multiple institutions.Clinical data of cancer patients aged over 20 years old, who received a total radiotherapy dose above 40 Gy, and who were treated with cepharanthin for more than 2 weeks between April 2007 and November 2012, were evaluated. Data from 65 patients(males: 31, females: 34)from 7 facilities were analyzed to assess efficacy and adverse events.The mean leukocyte count was significantly higher at the end of the treatment compared with the initial data.However, no significant differences were observed in erythrocyte and platelet counts.No adverse events attributed to cepharanthin were reported.Although this was a retrospective study, cepharanthin was found to be safe and significantly effective for the management of leukopenia caused by radiotherapy.
authors.affiliation: Dept. of Radiation Oncology, Kindai University Faculty of Medicine.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kanamori
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hiraoka
authors.forename: Noboru
authors.initials: N
authors.lastname: Fukuhara
authors.forename: Yukio
authors.initials: Y
authors.lastname: Oizumi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Danjo
authors.forename: Kensei
authors.initials: K
authors.lastname: Nakata
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Owaki
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044182:Benzylisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007962:Leukocytes; D007970:Leukopenia / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011837:Radiation-Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D052117:Benzodioxoles
chemical_list: D044182:Benzylisoquinolines; D011837:Radiation-Protective Agents; C006947:cepharanthine; D052117:Benzodioxoles